The FDA has approved Johnson & Johnson’s prostate cancer drug Erleada (apalutamide) for patients whose prostate cancer has spread. Already on the market for patients in the early stages of the ...
Pfizer and Astellas have bagged FDA approval for Xtandi in metastatic castration-sensitive prostate cancer (CSPC), cancelling out a brief lead for rival drug Erleada from Johnson & Johnson.
Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...
Johnson & Johnson's Q4 sales hit $22.52 billion, with strong growth in MedTech and oncology. 2025 guidance shows promising EPS and revenue forecasts.
Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ETCompany ParticipantsJessica Moore - Vice President, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback